Portolan Capital Management LLC Purchases 42,731 Shares of Lantheus Holdings, Inc. $LNTH

Portolan Capital Management LLC lifted its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 16.8% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 297,208 shares of the medical equipment provider’s stock after purchasing an additional 42,731 shares during the quarter. Portolan Capital Management LLC owned 0.45% of Lantheus worth $15,244,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Stanley Laman Group Ltd. lifted its holdings in shares of Lantheus by 38.7% in the 3rd quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock valued at $4,087,000 after acquiring an additional 22,229 shares during the last quarter. Quantbot Technologies LP bought a new stake in Lantheus during the third quarter worth approximately $1,847,000. American Assets Inc. bought a new stake in Lantheus during the third quarter worth approximately $872,000. Campbell & CO Investment Adviser LLC purchased a new stake in Lantheus during the third quarter valued at approximately $2,184,000. Finally, Assetmark Inc. raised its position in Lantheus by 20.1% during the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock valued at $6,078,000 after purchasing an additional 19,844 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

LNTH has been the subject of a number of recent research reports. Truist Financial lifted their target price on Lantheus from $82.00 to $89.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Mizuho increased their price target on Lantheus from $72.00 to $85.00 and gave the company an “outperform” rating in a report on Friday, February 27th. William Blair upgraded Lantheus from a “market perform” rating to an “outperform” rating in a research report on Thursday, February 26th. Citizens Jmp lifted their price objective on shares of Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research note on Tuesday, February 24th. Finally, Wall Street Zen upgraded shares of Lantheus from a “hold” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Seven equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $82.17.

Lantheus Stock Down 1.2%

Shares of NASDAQ:LNTH opened at $79.49 on Friday. The firm has a market capitalization of $5.17 billion, a PE ratio of 23.59 and a beta of -0.11. The business has a 50 day simple moving average of $70.53 and a two-hundred day simple moving average of $61.74. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $108.91. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.70 and a quick ratio of 2.51.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.50. Lantheus had a return on equity of 30.77% and a net margin of 15.15%.The firm had revenue of $406.79 million for the quarter, compared to the consensus estimate of $367.03 million. During the same period in the prior year, the business posted $1.59 earnings per share. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.